This new technology will facilitate functional genomics studies of late-onset Alzheimer's disease, drug discovery efforts targeting APP and characterization of the physiological functions of APP and its proteolytic fragments. The gene discussed is APP; the disease is early-onset autosomal dominant Alzheimer disease.